Phospho-PTPN11 (Tyr542) Antibody

What is PTPN11 and why is phosphorylation at Tyr542 significant?

PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), also known as SHP2, is a tyrosine phosphatase that plays critical roles in signal transduction from cell surface to nucleus. Phosphorylation at Tyr542 creates a binding site for GRB2 and other SH2-containing proteins, which is crucial for activating downstream signaling pathways including RAS/RAF/MAPK . This phosphorylation event occurs upon activation of receptor protein tyrosine kinases such as FLT3, PDGFRA, and PDGFRB . The Tyr542 phosphorylation site is located within the 508-557 amino acid region of human PTPN11 and serves as a key regulatory mechanism for its function in multiple signaling cascades .

To maintain optimal activity of Phospho-PTPN11 (Tyr542) antibodies:

• Store at -20°C for up to 1 year from receipt date

• Avoid repeated freeze-thaw cycles to prevent degradation

• For frequent use over short periods, store at 4°C (up to one month)

• Most preparations contain stabilizers such as 50% glycerol, 0.5% BSA, and 0.02% sodium azide in PBS

Proper aliquoting upon receipt can minimize freeze-thaw cycles and extend antibody shelf-life .

How specific are Phospho-PTPN11 (Tyr542) antibodies?

These antibodies are designed to detect endogenous levels of PTPN11 protein only when phosphorylated at Tyr542 . Specificity is typically achieved through:

• Affinity purification from antiserum using epitope-specific immunogens

• Validation against synthesized phosphopeptides corresponding to residues surrounding Tyr542

• Cross-reactivity testing across human, mouse, and rat samples

Depending on the manufacturer, these antibodies detect the phosphorylated form without significant cross-reactivity to non-phosphorylated PTPN11 or other phosphorylated proteins .

How does phosphorylation status of PTPN11 at Tyr542 differ across cancer types?

Research has revealed distinct patterns of PTPN11 Tyr542 phosphorylation across cancer types:

• Decreased phosphorylation observed in:

  • Breast cancer

  • Clear cell renal cell carcinoma (RCC)

  • Head and neck squamous cell carcinoma (HNSC)

  • Lung adenocarcinoma (LUAD)

• Increased phosphorylation observed in:

  • Melanoma (40% of specimens, n=15/38)

  • EGFRvIII-expressing glioblastoma cells

These differential phosphorylation patterns suggest context-dependent regulation of PTPN11 in cancer pathogenesis. For example, in LUAD, the reduced phosphorylation of PTPN11 at Tyr542 may affect downstream MAPK pathway activation, which could impact tumor progression and therapeutic response .

What controls the phosphorylation state of PTPN11 at Tyr542?

PTPN11 Tyr542 phosphorylation is regulated through multiple mechanisms:

• Kinase-mediated activation: Receptor tyrosine kinases including PDGFRA, PDGFRB, and FLT3 can phosphorylate PTPN11 at Tyr542 upon activation

• Phosphatase-mediated regulation:

  • PTPN1 and PTPN2 serve as phosphatases for PTPN11

  • Deletion of PTPN1 induces marked increase in SHP2 phosphorylation at Tyr542 when ALK-positive anaplastic large cell lymphoma (ALCL) cells are treated with inhibitors

• Feedback regulation:

  • PTPN11 can influence its own phosphorylation state through interactions with upstream signaling components

  • Oncogenic ALK and STAT3 repress PTPN1 transcription, indirectly affecting PTPN11 phosphorylation

This complex regulatory network highlights the importance of context-specific analysis when studying PTPN11 Tyr542 phosphorylation in different experimental systems.

How should researchers troubleshoot weak or non-specific signals in Western blot applications?

When encountering issues with Phospho-PTPN11 (Tyr542) antibody in Western blot:

• For weak signals:

  • Increase antibody concentration (start with 1:500 and adjust as needed)

  • Optimize protein loading (50-100 μg total protein recommended)

  • Enhance detection by using more sensitive chemiluminescent substrates

  • Ensure proper activation of signaling pathways that induce Tyr542 phosphorylation prior to cell lysis

• For non-specific signals:

  • Increase blocking time/concentration (5% BSA in TBST often works better than milk for phospho-epitopes)

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Validate with positive controls such as NIH/3T3 or C6 cell lysates

  • Consider using a phosphopeptide competition assay to confirm specificity

• For inconsistent results between experiments:

  • Standardize cell stimulation protocols

  • Maintain consistent sample preparation and protein denaturation conditions

  • Consider that different cell types may require optimization of signal detection parameters

What is the relationship between PTPN11 phosphorylation and oncogenic signaling pathways?

PTPN11 phosphorylation at Tyr542 integrates with multiple oncogenic pathways:

• RAS/MAPK pathway activation:

  • Phosphorylated PTPN11 positively regulates MAPK signal transduction

  • In melanoma, PTPN11 phosphorylation drives anchorage-independent colony formation and tumor growth

• PI3K/AKT signaling:

  • PTPN11 participates in PI3K-Akt signaling pathway regulation

  • KEGG pathway analysis revealed PTPN11 involvement in phosphatidylinositol 3-kinase signaling

• Receptor tyrosine kinase (RTK) signaling:

  • PTPN11 acts downstream of various RTKs

  • In EGFRvIII-expressing cells, PTPN11 recruitment to the receptor complex depends on its phosphorylation at Tyr542

• ALK signaling in lymphomas:

  • PTPN11 phosphorylation at Tyr542 increases upon PTPN1 deletion in ALK-positive lymphoma cells

  • Combined inhibition of ALK and SHP2 (PTPN11) is an effective approach to treat anaplastic large cell lymphoma

Understanding these pathway interactions is essential for interpreting PTPN11 phosphorylation data in the context of oncogenic signaling.

What stimulation conditions effectively induce PTPN11 Tyr542 phosphorylation for positive controls?

To generate reliable positive controls for Phospho-PTPN11 (Tyr542) detection:

• Cell line selection:

  • NIH/3T3 and C6 cells have been validated as positive samples

  • Cell lines expressing active receptor tyrosine kinases (e.g., PDGFR, EGFR) are suitable

• Stimulation protocols:

  • PDGF stimulation (25-50 ng/ml for 5-15 minutes)

  • EGF stimulation (50-100 ng/ml for 5-10 minutes)

  • Serum stimulation (10% FBS for 15-30 minutes after starvation)

• Receptor activation:

  • Expression of constitutively active receptor mutants (e.g., EGFRvIII)

  • Pervanadate treatment (100 μM for 10 minutes) to inhibit endogenous phosphatases

• Sample preparation timing:

  • Lysis should occur rapidly after stimulation to capture transient phosphorylation events

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

These approaches provide reliable positive controls for validating antibody performance and experimental conditions.

How should researchers normalize phospho-PTPN11 (Tyr542) signals for accurate quantification?

For accurate quantification of phospho-PTPN11 (Tyr542) levels:

• Recommended normalization strategies:

  • Normalize to total PTPN11 protein using separate antibodies detecting non-phosphorylated forms

  • Use housekeeping proteins (β-actin, GAPDH) as loading controls

  • For immunofluorescence, normalize to DAPI nuclear staining

• Advanced normalization approaches:

  • Utilize on-blot markers spanning the molecular weight range

  • Consider normalization to multiple housekeeping proteins

  • For accurate phosphorylation status assessment, calculate phospho-PTPN11/total PTPN11 ratios

• Technical considerations:

  • Strip and reprobe membranes carefully to avoid protein loss

  • For double immunofluorescence, ensure minimal spectral overlap

  • When using image analysis software, define consistent parameters for quantification across samples

Proper normalization is critical for meaningful comparisons across different experimental conditions or patient samples.

What additional phosphorylation sites on PTPN11 should be examined in parallel with Tyr542?

For comprehensive analysis of PTPN11 phosphorylation status and function:

• Key additional phosphorylation sites:

  • Tyr580: Often phosphorylated alongside Tyr542 and creates binding sites for SH2-containing proteins

  • Tyr584: Shows altered phosphorylation in breast cancer and clear cell RCC

  • Ser36: Exhibits reduced phosphorylation in HNSC and clear cell RCC

  • Ser562: Shows decreased phosphorylation in breast cancer

• Functional relationships between sites:

  • Tyr542 and Tyr580 phosphorylation may have cooperative effects on PTPN11 activation

  • Different sites may be preferentially phosphorylated depending on the upstream kinase

• Experimental approach:

  • Use antibodies specific to each phosphorylation site

  • Consider phospho-proteomic approaches for unbiased assessment of multiple sites

  • Correlate phosphorylation patterns with downstream signaling events

Analyzing multiple phosphorylation sites provides a more complete understanding of PTPN11 activation status and its functional consequences.

How does PTPN11 Tyr542 phosphorylation contribute to cancer development and progression?

PTPN11 Tyr542 phosphorylation influences cancer biology through several mechanisms:

• Transformation and tumorigenesis:

  • In melanoma, PTPN11 plays oncogenic roles by driving anchorage-independent colony formation and tumor growth

  • PTPN11 E76K expression significantly enhances melanoma tumorigenesis in Pten- and Cdkn2a-null mice

  • EGFRvIII-induced oncogenesis requires functional PTPN11 and increases its phosphorylation at Tyr542

• Metastasis and invasion:

  • PTPN11 regulates tumor cell proliferation, invasion, and metastasis

  • Altered phosphorylation status correlates with different cancer progression stages

• Cell cycle regulation:

  • Inhibition of PTPN11 blocks cell cycle progression at different phases in glioblastoma cells

  • PTPN11 contributes to cancer cell proliferation through cell cycle regulation

• Therapeutic resistance:

  • Altered PTPN11 phosphorylation contributes to resistance mechanisms in ALK-inhibitor treated lymphomas

  • Combined targeting of ALK and SHP2 (PTPN11) can overcome resistance

These findings highlight the context-dependent roles of PTPN11 Tyr542 phosphorylation in cancer biology.

What are the methodological considerations when assessing PTPN11 Tyr542 phosphorylation in clinical samples?

When analyzing clinical specimens for PTPN11 Tyr542 phosphorylation:

• Sample preparation:

  • Flash-freeze tissues immediately to preserve phosphorylation status

  • For FFPE samples, use phospho-specific antibodies validated for IHC

  • Include phosphatase inhibitors in all extraction buffers

• Technical validation:

  • Use appropriate positive controls (e.g., cell lines with known phosphorylation status)

  • Perform antibody validation with peptide competition assays

  • Consider parallel analysis with orthogonal techniques (WB, IHC, IF)

• Interpretation challenges:

  • Account for tumor heterogeneity by analyzing multiple regions

  • Consider the impact of prior treatments on phosphorylation status

  • Correlate with other biomarkers like total PTPN11 expression

• Scoring systems:

  • Develop consistent scoring criteria for immunohistochemical assessment

  • Consider both intensity and percentage of positive cells

  • Use digital pathology tools for quantitative assessment when possible

These methodological considerations help ensure reliable and reproducible assessment of PTPN11 Tyr542 phosphorylation in clinical samples.

How can phospho-PTPN11 (Tyr542) antibodies be used to evaluate response to targeted therapies?

Phospho-PTPN11 (Tyr542) antibodies provide valuable tools for monitoring treatment response:

• Pharmacodynamic biomarker applications:

  • Monitor target engagement of SHP2 inhibitors in preclinical and clinical studies

  • Track RTK inhibitor effects on downstream signaling

  • Assess pathway reactivation in resistance settings

• Combination therapy research:

  • In ALK-positive lymphomas, combined inhibition of ALK and SHP2 showed synergistic effects

  • Monitoring Tyr542 phosphorylation can guide rational combination strategies

  • Changes in phosphorylation patterns may predict sensitivity to combination approaches

• Resistance mechanism elucidation:

  • Increased SHP2 phosphorylation at Tyr542 was observed in ALK inhibitor-resistant cells

  • PTPN1 deletion induced marked increase in SHP2 phosphorylation at Tyr542

  • Monitoring phosphorylation changes can identify bypass mechanisms

• Practical workflow:

  • Collect pre-treatment and on-treatment biopsies when possible

  • Use cell line models to establish expected phosphorylation changes

  • Correlate phosphorylation changes with clinical outcomes

These applications demonstrate how phospho-PTPN11 (Tyr542) antibodies contribute to therapeutic development and personalized medicine approaches.

How should researchers address contradictory findings about PTPN11 Tyr542 phosphorylation across different cancer types?

When confronting contradictory results regarding PTPN11 phosphorylation:

• Biological context considerations:

  • PTPN11 shows inconsistent expression and phosphorylation across different tumors

  • The role of PTPN11 may be context-dependent, acting as an oncogene or tumor suppressor depending on cellular context

  • Different upstream activators may predominate in different cancer types

• Methodological reconciliation:

  • Compare antibody specificities and epitopes used across studies

  • Evaluate cell stimulation conditions and lysis procedures

  • Consider the impact of tumor heterogeneity and microenvironment

• Integrative analysis approaches:

  • Correlate phosphorylation with genetic alterations in the same samples

  • Consider phosphorylation of multiple sites simultaneously

  • Analyze phosphorylation in relation to activity of upstream kinases and downstream effectors

• Experimental validation strategies:

  • Use genetic approaches (e.g., CRISPR) to validate functional relationships

  • Perform rescue experiments with phospho-mimetic or phospho-dead mutants

  • Apply multiple orthogonal techniques to confirm observations

This systematic approach helps reconcile apparently contradictory findings about PTPN11 Tyr542 phosphorylation across cancer types.

What controls and validation steps are essential when publishing research using phospho-PTPN11 (Tyr542) antibodies?

For rigorous scientific publications involving phospho-PTPN11 (Tyr542) antibodies:

• Essential controls:

  • Positive controls: Stimulated cell lines known to induce Tyr542 phosphorylation

  • Negative controls: Unstimulated cells or phosphatase-treated lysates

  • Specificity controls: Peptide competition or phospho-null mutants

  • Loading controls: Total PTPN11 detection on parallel blots or after stripping

• Antibody validation documentation:

  • Report complete antibody information including manufacturer, catalog number, and lot

  • Document antibody dilution, incubation conditions, and detection methods

  • Demonstrate specificity with appropriate controls

  • Include all antibody validation data in supplementary materials

• Experimental validation approaches:

  • Confirm key findings with at least two independent antibody clones when possible

  • Validate with genetic approaches (siRNA knockdown, CRISPR knockout)

  • Correlate phosphorylation with functional outcomes

  • Use phospho-mimetic or phospho-dead mutants for mechanistic studies

• Data presentation standards:

  • Show representative images of full western blots including molecular weight markers

  • Present quantitative data from multiple independent experiments

  • Describe normalization methods in detail

  • Clearly state statistical analysis approaches

These practices ensure research reproducibility and credibility when using phospho-PTPN11 (Tyr542) antibodies.

How might single-cell analysis techniques advance our understanding of PTPN11 Tyr542 phosphorylation heterogeneity?

Single-cell technologies offer promising opportunities for PTPN11 research:

• Emerging methodological approaches:

  • Single-cell mass cytometry (CyTOF) with phospho-specific antibodies

  • Single-cell Western blotting for protein isoform resolution

  • Proximity ligation assays (PLA) to visualize protein interactions in situ

  • Single-cell phosphoproteomics for unbiased profiling

• Research questions addressable with single-cell techniques:

  • Intratumoral heterogeneity of PTPN11 phosphorylation

  • Correlation between phosphorylation status and cell state/differentiation

  • Temporal dynamics of phosphorylation in response to stimuli

  • Co-occurrence patterns with other phosphorylation events

• Technical considerations and challenges:

  • Need for highly specific antibodies compatible with single-cell techniques

  • Preservation of phosphorylation status during single-cell isolation

  • Integration of phospho-protein data with transcriptomic information

  • Computational approaches for meaningful data interpretation

Single-cell analysis could reveal functionally distinct cell populations based on PTPN11 phosphorylation status that are masked in bulk analyses.

What are the emerging approaches for targeting PTPN11 phosphorylation events therapeutically?

Therapeutic strategies targeting PTPN11 and its phosphorylation are evolving:

• Direct PTPN11/SHP2 inhibition approaches:

  • SHP099 has shown efficacy in NRAS Q61K-mutant melanoma

  • Combined ALK and SHP2 inhibition showed synergistic effects in lymphoma

  • Allosteric inhibitors targeting the auto-inhibitory interface

• Modulation of phosphorylation status:

  • Targeting upstream kinases that phosphorylate PTPN11 at Tyr542

  • Enhancing activity of phosphatases like PTPN1 and PTPN2 that regulate PTPN11

  • Disrupting interactions dependent on Tyr542 phosphorylation

• Novel therapeutic modalities:

  • Proteolysis targeting chimeras (PROTACs) directed against PTPN11

  • Antisense oligonucleotides to modulate PTPN11 expression

  • Synthetic lethal approaches in tumors with altered PTPN11 signaling

• Rational combination strategies:

  • Combining PTPN11 inhibition with RTK inhibitors

  • Targeting parallel pathways activated by PTPN11 phosphorylation

  • Sequential therapy approaches based on resistance mechanisms

These emerging approaches hold promise for translating our understanding of PTPN11 phosphorylation into therapeutic strategies.